Please assess the completion status of the following clinical trial:

Trial Title: AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed pregnancy;~* 18 years or older;~* Two or more unexplained pregnancy loss before the 10th week of gestation, AND/OR one or more unexplained pregnancy loss at or beyond the 10th week of gestation;~* One or more APS laboratory criteria present, according to the revised Sapporo criteria;~Exclusion Criteria:~* Greater than 11 weeks +6 days gestational age at time of randomization;~* Indication(s) for prophylactic or therapeutic-dose anticoagulation;~* Contraindication to heparin or aspirin;~* Received 7 or more doses of LMWH;~* Previous participation in the trial;~* Geographic inaccessibility;~* Refused consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care Arm (Type: ACTIVE_COMPARATOR): Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
- Experimental Arm (Type: EXPERIMENTAL): Open-label low-dose Aspirin 81 mg daily from randomization until delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).